Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

1(20.0%)

Early Phase 1

1(20.0%)

5Total

N/A(3)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06959966Early Phase 1Completed

Effects of Oligo-fucoidan on Leiomyoma Patients

Role: collaborator

NCT04066660Not ApplicableTerminated

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Role: lead

NCT04597476Phase 2Recruiting

A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck

Role: lead

NCT04715776Not ApplicableUnknown

Supplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-Diabetes

Role: collaborator

NCT03130829Not ApplicableWithdrawn

To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

Role: lead

All 5 trials loaded